Idenix Pharmaceuticals Reports Favorable Pharmacokinetic Data for IDX320, a Potent, Multi-Genotypic Protease Inhibitor for the Treatment of Hepatitis C
Advertisement
- IDX320 pharmacokinetic data in healthy volunteers suggest potential for once-daily dosing in HCV-infected patients